Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilar Insulin Market Access" report to their offering.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.
More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations.
As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.
Key Topics Covered:
1. EXECUTIVE SUMMARY
2. US
- Insights and strategic recommendations
- US payers are adopting a wait-and-see approach for biosimilar Basaglar
- Bibliography
3. FIVE MAJOR EU MARKETS
- Insights and strategic recommendations
- Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
- Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
- Payers use biosimilars to pressure originators on pricing
- Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
- Patient switching requires significant discounts of at least 30%
- Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
- Bibliography
4. METHODOLOGY
For more information about this report visit http://www.researchandmarkets.com/research/5k4v4m/biosimilar
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors
